Pharmaceuticals

Global Aurora Kinase B Market 2026–2030: Forecast Insights for Business Planning

February 12, 2026February 12, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the aurora kinase b market from 2026–2035 with trusted insights from The Business Research Company

How much larger will the Aurora Kinase B Market be in 2030 compared with 2026?

The aurora kinase b market has experienced substantial growth in its size over recent years. It is projected to increase from $1.27 billion in 2025 to $1.43 billion in 2026, showing a compound annual growth rate (CAGR) of 12.0%. This expansion during the historic period can be attributed to factors such as advancements in molecular oncology research, the identification of aurora kinase b as a cancer target, an expansion of clinical trial infrastructure, increasing investment in targeted cancer therapies, and progress in kinase inhibitor development.

The aurora kinase b market is projected to experience significant expansion in the coming years. By 2030, its valuation is anticipated to reach $2.22 billion, exhibiting a compound annual growth rate (CAGR) of 11.7%. This anticipated growth during the forecast period stems from factors such as a heightened demand for precision cancer treatments, the broadening adoption of personalized medicine strategies, an uptick in oncology clinical trial endeavors, increased capital allocation towards innovative kinase inhibitors, and enhanced regulatory backing for targeted oncology pharmaceuticals. Key trends influencing this period encompass the accelerated development of selective aurora kinase b inhibitors, a greater focus on combination oncology regimens, the enlargement of precision oncology drug development pipelines, an intensified interest in mitotic targeted treatments, and more effective biomarker-based patient selection.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20496&type=smp

What Drivers Are Guiding Growth Patterns In The Aurora Kinase B Market?

The increasing prevalence of cancer is projected to fuel the expansion of the aurora kinase B market moving forward. Cancer refers to a collection of illnesses marked by the uncontrolled multiplication and dispersion of abnormal cells, capable of invading adjacent tissues and spreading to distant parts of the body. The surge in cancer cases can be attributed to elements like an aging demographic, shifts in lifestyle, environmental exposures, and advancements in detection and diagnostic methods. Aurora kinase B holds a crucial function in mitosis, and its excessive expression is associated with chromosomal instability and the advancement of cancer. Given its role in the division of tumor cells, it is frequently a target in cancer treatments. For example, in February 2024, data from the World Health Organization, an intergovernmental body based in Switzerland, revealed approximately 20 million new cancer cases in 2022, alongside 9.7 million fatalities. Projections indicate that by 2050, new cancer diagnoses are anticipated to surpass 35 million, marking a 77% rise compared to 2022 figures. Consequently, the escalating occurrence of cancer is a key impetus for the expansion of the aurora kinase B market.

How Is The Aurora Kinase B Market Divided Into Segments?

The aurora kinase b market covered in this report is segmented –

1) By Type: AZD-2811, CS-2164, Danusertib, Ilorasertib, NMI-900, Other Types

2) By Application: Anaplastic Large Cell Lymphoma, Kidney Cancer, Lung Cancer, Prostate Cancer, Other Applications

3) By End-User: Hospitals, Research Institutes, Diagnostic Laboratories, Other End-Users

Subsegments:

1) By AZD-2811: Phase I Clinical Trials AZD-2811, Preclinical Development of AZD-2811, AZD-2811 in Combination Therapy, Targeted Cancer Treatment with AZD-2811

2) By CS-2164: Phase II Clinical Trials CS-2164, Preclinical Development of CS-2164, CS-2164 in Targeted Cancer Therapy, CS-2164 Combination Therapy in Clinical Studies

3) By Danusertib: Phase III Clinical Trials Danusertib, Danusertib for Hematological Malignancies, Danusertib for Solid Tumors, Combination Therapy with Danusertib

4) By Ilorasertib: Preclinical Development of Ilorasertib, Ilorasertib in Solid Tumor Treatment, Phase I and II Clinical Trials of Ilorasertib, Ilorasertib in Combination with Chemotherapies

5) By NMI-900: NMI-900 in Early-Stage Clinical Trials, NMI-900 for Targeted Cancer Therapy, Preclinical Studies of NMI-900, NMI-900 Combination Therapy Trials

6) By Other Types: Other Aurora Kinase B Inhibitors in Development, Novel Targeted Aurora Kinase B Drugs, Combination Therapies Involving Aurora Kinase B Inhibitors, Investigational Aurora Kinase B Inhibitors in Oncology

Which Trends Are Influencing The Performance And Direction Of The Aurora Kinase B Market?

Companies operating within the aurora kinase B market are actively engaged in creating innovative products, such as aurora kinase inhibitors, specifically to target and interrupt key processes in cellular division. These aurora kinase inhibitors are medications formulated to obstruct the functioning of Aurora kinases, which are vital for cell division, thereby disrupting the rapid growth of cancer cells and potentially curbing tumor expansion. For example, in June 2023, Ellipses Pharma, a biotechnology firm based in the UK, announced that its EP0042, a dual FLT-3 and Aurora kinase inhibitor, had received approval from the U.S. Food and Drug Administration (FDA). EP0042 is being advanced as a therapeutic option for acute myeloid leukemia (AML) and functions as an inhibitor targeting both FLT3 and Aurora kinase. This method is specifically tailored for AML patients who have developed a resistance to FLT3 inhibitors. Studies have indicated that the dual inhibition of FLT3 and Aurora kinase is capable of overcoming acquired resistance to selective FLT3 inhibition in both in vitro and in vivo settings.

Which Key Players Are Driving Competition In The Aurora Kinase B Market?

Major companies operating in the aurora kinase b market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Amgen Inc., Astellas Pharma Inc., Promega Corporation, Rigel Pharmaceuticals Inc., Tocris Bioscience, BPS Bioscience Inc., Advenchen Laboratories LLC, Shenzhen Chipscreen Biosciences Co. Ltd., Cyclacel Pharmaceuticals Inc., Sareum Holdings plc

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/aurora-kinase-b-global-market-report

Which Region Is Projected To Lead The Aurora Kinase B Market During The Forecast Period?

North America was the largest region in the aurora kinase B market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the aurora kinase b market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Aurora Kinase B Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20496&type=smp

Browse Through More Reports Similar to the Global Aurora Kinase B Market 2026, By The Business Research Company

Cancer Biologics Market Report 2026

https://www.thebusinessresearchcompany.com/report/cancer-biologics-global-market-report

Skin Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/skin-cancer-drugs-global-market-report

Pancreatic Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/pancreatic-cancer-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795